Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Vox Sang ; 119(1): 27-33, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37986640

ABSTRACT

BACKGROUND AND OBJECTIVES: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels. MATERIALS AND METHODS: Four-hundred donors were enrolled in ConPlas-19. The presence and titres of anti-SARS-CoV-2 antibodies were evaluated by EUROIMMUN anti-SARS-CoV-2 S1 IgG ELISA. RESULTS: A majority of 80.3% of ConPlas-19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti-SARS-CoV-2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24-3.42), with more than 7 days of COVID-19 symptoms (RR 1.89; 95% CI 1.05-3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16-5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91-3.06). CONCLUSION: SARS-CoV-2 CP candidate donors' age, duration of COVID-19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID-19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks.


Subject(s)
COVID-19 , SARS-CoV-2 , Female , Humans , Male , Antibodies, Neutralizing , Antibodies, Viral , Blood Donors , COVID-19/therapy , COVID-19 Serotherapy , Immunization, Passive/methods , Immunoglobulin G , Clinical Trials as Topic
2.
J Clin Med ; 12(19)2023 Sep 24.
Article in English | MEDLINE | ID: mdl-37834817

ABSTRACT

Postpartum hemorrhage (PPH) remains a significant obstetric emergency worldwide and a leading cause of maternal death. However, it is commonly underreported, which can represent a major concern for maternal morbidity and mortality. This retrospective case series study analyzed patients with red blood cell transfusion (RBCt) in the postpartum period over a four-year interval at a specific center. A total of 18,674 patients delivered between January 2018 and December 2021. Patients with postpartum RBCt were classified into two groups: those with identified PPH (i-PPH) and those without (non-i-PPH). Clinical variables, delivery details, blood loss data, and treatment information were collected. Statistical analysis involved a comparison of variables between the i-PPH and non-i-PPH groups. Univariate and multivariate analyses were performed, aiming to identify significant associations between the clinical variables and a lack of PPH identification. The incidence of RBCt was 1.26% (236 cases). Patients receiving RBCt had higher rates of cesarean delivery, twin pregnancy, labor induction, and previous cesarean section. Among patients with postpartum RBCt, 34.3% lacked an identified PPH. The rarity of postpartum RBCt contrasts with the increasing rates of PPH, highlighting the importance of diagnosing PPH and postpartum anemia. A strategy of systematic quantification of blood loss during delivery could help detect PPH and anemia before adverse consequences occur.

5.
Int J Clin Pharm ; 41(5): 1143-1147, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31256332

ABSTRACT

Background Severe non-chemotherapy drug-induced neutropenia is a rare idiosyncratic drug reaction that is considered potentially fatal. Objective To report, in terms of drug safety surveillance, the results of an institutional strategy for NCDIN. Method An observational and prospective study including all adult patients who received filgrastim for the treatment of NCDIN from June 2015 to December 2017 was carried out by hematologists and clinical pharmacists. Results 13 patients with severe NCDIN were included in the study. The median age was 51 (range 24-80) years old and 46.2% were male. Seven patients had one or more negative prognostic factors (age > 65 years, renal impairment, autoimmune diseases and/or a neutrophil count at diagnosis < 0.1 × 109 cells/L). A single drug was identified as causative in 3 patients, while in 10 cases, 2-3 drugs were considered as potentially causative. The most frequent drugs were metamizole, piperacillin/tazobactam, dexketoprofen and linezolid, among others. Seven patients developed NCDIN during their hospital stay while 6 were admitted to the emergency department. Patients were using a median of 11 drugs (IQR 8-15) at the time of diagnosis. No deaths were recorded. Conclusion Metamizole and piperacillin/tazobactam are the most common drugs linked to non-chemotherapy drug-induced neutropenia in our cohort.


Subject(s)
Filgrastim/therapeutic use , Hematologic Agents/therapeutic use , Neutropenia/chemically induced , Neutropenia/therapy , Pharmacovigilance , Adult , Aged , Aged, 80 and over , Disease Management , Emergency Medical Services/statistics & numerical data , Female , Humans , Leukocyte Count , Male , Middle Aged , Patient Safety , Prognosis , Prospective Studies , Young Adult
6.
Am J Nephrol ; 28(1): 76-82, 2008.
Article in English | MEDLINE | ID: mdl-17914248

ABSTRACT

BACKGROUND/AIMS: This study aimed to test the viability and functionality of fresh and cryopreserved human hyperplastic parathyroid glands cultured in vitro. METHODS: Small fragments of 18 parathyroid glands from 18 patients with secondary hyperparathyroidism were cultured in vitro, freshly or after cryopreservation, during 60 h. Cell viability and functionality of the parathyroid fragments exposed to calcium and calcitriol were studied. RESULTS: Human parathyroid glands obtained from renal patients with secondary hyperparathyroidism maintained their viability and functionality for 60 h in culture. Sixty percent of the fresh but only 10% of the cryopreserved parathyroid glands showed the expected response with higher intact parathyroid hormone secretion when cultured with 0.6 mM calcium compared to 1.2 mM calcium. On the contrary, 44 of fresh and 40% of cryopreserved glands behaved in the same manner, showing a similar decrease in intact parathyroid hormone synthesis and secretion when cultured with calcitriol (10(-8)M). CONCLUSION: These results demonstrate differences in the response to calcium between fresh and cryopreserved glands and no differences in the response to calcitriol. This in vitro culture method may be useful to discriminate between responsive and nonresponsive hyperplastic human parathyroid glands.


Subject(s)
Cryopreservation/methods , Hyperparathyroidism, Secondary/pathology , Parathyroid Glands/pathology , Renal Insufficiency, Chronic/complications , Calcitriol/pharmacology , Calcium/pharmacology , Cell Survival , Cells, Cultured , Female , Gene Expression/drug effects , Humans , Hyperplasia , In Vitro Techniques , Male , Parathyroid Glands/drug effects , Parathyroid Glands/metabolism , Parathyroid Hormone/genetics , Parathyroid Hormone/metabolism , Vitamins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...